

4. Literatur

1. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. *Cancer Metastasis Rev* 2006; **25**: 9-34.
2. Streuli CH. Extracellular matrix remodelling and cellular differentiation. *Curr Op in Cell Biol* 1999; **11**: 634-40.
3. Hockenberry DM. MMPs in unusual places. *Am J Pathol* 2006; **169**: 1101-3.
4. Bernal F, Hartung HP, Kieseier BC. Tissue mRNA expression in rat of newly described metalloproteinases. *Biol Res* 2005; **38**: 267-71.
5. Gimeno-Garcia AZ, Santana-Rodriguez A, Jimenez A et al. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. *Eur J Cancer* 2006; in press.
6. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. *Biochimie* 2005; **87**: 287-97.
7. Klein G, Vellenga E, Fraaije MW et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. *Crit Rev Oncol Hematol* 2004 May. 2004; **50**: 87-100.
8. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). *Curr Gene Ther* 2002; **2**: 255-271.
9. Chirco R, Liu XW, Jung KK et al. Novel Functions of TIMPs in signaling. *Cancer Metastasis Rev* 2006; **25**: 99-113.
10. Liu XW, Taube ME, Jung KK et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. *Cancer Res* 2005; **65**: 898-906.
11. Bode W, Fernandez-Catalan C, Grams F et al. Insights into MMP-TIMP interactions. *Ann N Y Acad Sci* 1999; **878**: 73-91.
12. Woessner JF, Nagase H. Matrix Metalloproteinases and TIMPs. *Oxford University Press*. 2000.
13. Olson MW, Gervasi DC, Mobashery S et al. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. *J Biol Chem* 1997; **272**: 29975-83.
14. Toth M, Chvyrkova I, Bernardo MM et al. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. *Biochem Biophys Res Commun* 2003; **308**: 386-95.
15. Brand K, Baker AH, Perez-Canto A et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. *Cancer Res* 2000; **60**: 5723-30.
16. Griswold DP, Jessup DE. A colon tumor model for anticancer agent evaluation.. *Cancer* 1975; **36**: 2441-4.
17. Krüger A, Schirrmacher V, von Hoegen P. Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. *Int J Cancer* 1994; **58**: 275-84.
18. Krüger A, Fata JE, Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. *Blood* 1997; **90**: 1993-2000.
19. Liu Q, Zaiss AK, Colarusso P et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. *Hum Gene Ther* 2003; **14**: 627-43.

20. Li C, Bowles DE, van Dyke T, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. *Cancer Gene Ther* 2005; **12**: 913-25.
21. Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. *Gene Ther* 2005; **12** Suppl 1: S18-27.
22. Guan M, Rodriguez-Madoz JR, Alzuguren P et al. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. *Cancer Res* 2001; **66**: 1620-9.
23. Yan L, Moses MA et al. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. *Am J Pathol* 2001; **158**: 1185-90.
24. Acuff HB, Carter KJ, Fingleton B et al. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. *Cancer Res* 2000; **66**: 259-66.
25. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science* 2002; **295**: 2387-92.
26. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. *Cancer Metastasis Rev* 2006; **25**: 115-36.
27. Krüger A, Arlt MJ, Gerg M et al. Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor. *Cancer Res* 2005; **65**: 3523-26.
28. Rhee JS, Diaz R, Korets L, Hodgson et al. TIMP-1 alters susceptibility to carcinogenesis. *Ann Surg* 2004; **64**: 952-61.
29. Roeb E, Behrmann I, Grotzinger J et al. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. *FASEB J* 2000; **14**: 1671-3.
30. Wei S, Chen Y, Chung L et al. Novel Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain. *J Biol Chem* 2003; **278**: 9831-34.
31. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. *Cell* 1997; **91**: 439-42.
32. Werb Z, Yan Y. A cellular striptease act. *Cell* 1998; **282**: 1279-80.
33. Rundhaug JE. Matrix metalloproteinases and angiogenesis. *J Cell Mol Med* 2005; **9**: 267-85.
34. Yu Q, Stamenkovic I. Cell surface localized matrix metalloproteinase-9 proteolytically activates TGF- β and promotes tumor invasion and angiogenesis. *Genes Dev* 2000; **14**: 163-76.
35. Sopata I, Dancewicz AM. Presence of a gelatine-specific protease from human leukocytes and its activation. *Biochim Biophys Acta* 1974; **370**: 510-523.
36. Swallow CJ, Murray MP, Guillem JG. Metastatic colorectal cells induce matrix metalloproteinase release by human monocytes. *Clin Exp Metastasis* 1996; **14**: 3-11.
37. Sova P, Ren XW, Ni S, et al. A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver Metastases. *Mol Ther* 2005; **9**: 496-509.
38. Demers M, Magnaldo T, St-Pierre Y. A Novel Function for Galectin-7: Promoting Tumorigenesis by Up-regulating MMP-9 Gene Expression. *Cancer Res* 2005; **65**: 5205-10.
39. Oakley F, Meso M, Iredale JP et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. *Gastroenterology* 2005; **128**: 108-20.
40. Friedman SL. Transcriptional regulation of stellate cell activation. *Journal of Gastroenterology and Hepatology* 2006; **21**: S79-S83.